Key result
CircuLite Synergy partial support device yields ~50% survival to discharge in fragile end-stage heart failure.
Why the study?
Despite endorsement and increasing confidence in VAD technology for end-stage HF, implant numbers remain steady due to complications limiting use in fragile patients.
Does the CircuLite Synergy partial support device improve outcomes in fragile, elderly patients with end-stage heart failure?
Observational (n=6)
No
Does the CircuLite Synergy partial support device improve outcomes in fragile, elderly patients with end-stage heart failure?
A superficial partial support device (CircuLite Synergy) demonstrated feasibility and symptom relief in a small cohort of frail, elderly patients with end-stage heart failure, though the device is no longer available.
Answers are grounded in this paper and cite their sources.
Supports feasibility in frail elderly end-stage HF; leaves open durable benefit and generalizability for future partial-support devices.
Ventricular assist devices (VADs) are considered the standard of care for end-stage heart failure (HF) patients. Despite increasing confidence in the technology, evidence data, endorsement by scientific societies and guidelines, the number of implants reached a steady state and is not increasing at the expected pace. This is most likely related to complications that are still burdening the technology and consequently excluding the most needy, ill, and fragile population. In this manuscript we are reporting a single-center experience in a very fragile, elderly and end-stage HF population, with a superficial, partial support device: the CircuLite Synergy. The patients were included in the pre-CE mark clinical study and consequently the device underwent technical adjustment during the support, based on the complications recorded. At our institution were implanted 6 patients overall: 3 patients survived to discharge and 2 survived up to 5 years. Most of the complications recorded were due to patients' frailty and overall clinical conditions. The initial experience with the CircuLite Synergy device is proving that a more "superficial" device might be more tolerable in an elderly, frail population. Partial support has proven hemodynamically efficacious and efficient in relieving heart failure symptoms, improving medical therapy tolerability, and improving quality of life. Unfortunately, the technology was not made available due to financial uncertainty and poor management, but we hope that once the concept has been proved someone will collect the legacy.
No takes yet. Share an insight, caveat, or question.
Barbone et al. (2020) conducted an observational in End-stage heart failure (n=6). CircuLite Synergy partial support device was evaluated on Survival to discharge. Implantation of the CircuLite Synergy partial support device in 6 fragile, elderly patients with end-stage heart failure resulted in 3 surviving to discharge and 2 surviving up to 5 years.
Synapse has enriched 10 related papers. Consider them for comparative context: